The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with New Malignancies and Recurrence of Pre-existing Malignancy
Timeframe: Up to 15 years
Number of Participants with New Incidence or Exacerbation of a Pre-existing Neurologic Disorder
Timeframe: Up to 15 years
Number of Participants with New Incidence or Exacerbation of a Pre-existing Rheumatologic or Other Autoimmune Disorder
Timeframe: Up to 15 years
Number of Participants with New Incidence of Grade Greater than or Equal to (>=) 3 Hematologic Disorder Including Hypogammaglobulinemia
Timeframe: From year 1 up to year 5
Number of Participants with Serious Hematologic Disorder, including Hypogammaglobulinemia
Timeframe: From year 6 up to year 15
Number of Participants with New Incidence of Grade >= 3 Infection
Timeframe: From year 1 up to year 5
Number of Participants with Serious Infection
Timeframe: From year 6 up to year 15
Number of Participants with Serious Adverse Events (SAEs)
Timeframe: From year 1 up to year 5
Number of Participants with Related Serious Adverse Events Assessed by the Investigator
Timeframe: From year 6 up to year 15